OS Therapies (NYSE:OSTX) Earns Buy Rating from D. Boral Capital

Posted by ABMN Staff on Apr 2nd, 2025

OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $20.00 price target on the stock.

Separately, Maxim Group upped their price target on OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, January 16th.

Check Out Our Latest Analysis on OS Therapies

OS Therapies Stock Performance

NYSE:OSTX opened at $1.33 on Monday. OS Therapies has a 52 week low of $1.33 and a 52 week high of $7.00. The company has a fifty day simple moving average of $1.85 and a two-hundred day simple moving average of $2.71.

Insiders Place Their Bets

In related news, major shareholder Shalom Auerbach sold 100,000 shares of OS Therapies stock in a transaction on Friday, February 14th. The shares were sold at an average price of $2.84, for a total transaction of $284,000.00. Following the sale, the insider now directly owns 2,431,211 shares in the company, valued at $6,904,639.24. This trade represents a 3.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.80% of the stock is owned by company insiders.

Institutional Trading of OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new stake in OS Therapies Inc (NYSE:OSTX – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

(Get Free Report)

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.